Vivaldi Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Vivaldi Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,722	Closed	-$218K	–	337
2021 Q2	$218K	Sell	1,722 -213	-11%	-$25.9K	0.04%	216
2021 Q1	$206K	Buy	1,935 +27	+1%	+$4.08K	0.04%	226
2020 Q4	$292K	Buy	+1,908	New	+$226K	0.06%	189
2018 Q4	–	Sell	-5,006	Closed	-$222K	–	201
2018 Q3	$222K	Buy	5,006 +6	+0.1%	+$314	0.12%	121
2018 Q2	$294K	Buy	+5,000	New	+$285K	0.24%	98

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vivaldi Capital Management's CRSP Position: Q3 2021 in Review

Vivaldi Capital Management sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 1,722 shares — an estimated $218K sold.

Vivaldi Capital Management first reported a position in CRSP in Q2 2018 and held it in 5 quarters. The position peaked at $294K in Q2 2018. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

Vivaldi Capital Management reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
Vivaldi Capital Management sold 1,722 CRISPR Therapeutics shares in Q3 2021, an estimated $218K.
Vivaldi Capital Management first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 5 quarters.
Vivaldi Capital Management's CRISPR Therapeutics position peaked at $294K in Q2 2018.
473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Vivaldi Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.